Opinion
Video
Author(s):
Key opinion leaders examine recent evidence on acquired BTK inhibitor resistance in chronic lymphocytic leukemia and analyze its implications for treatment sequencing decisions in clinical practice.
Dr Coombs to Group:What implications may these findings have on treatment sequencing? Is there a potential role of testing for acquired mutations upon disease progression?
DESTINY-Breast12 Data Support T-DXd Use in HER2+ Breast Cancer, Irrespective of Brain Mets
Tivozanib Monotherapy Bests Lower-Dose Tivozanib Plus Nivolumab in Metastatic RCC
Frontline BMS-986012 Plus Nivolumab/Chemotherapy Shows Promise in ES-SCLC
Belzutifan Maintains PFS, ORR Benefits in Previously Treated Advanced Clear Cell RCC
2 Commerce Drive
Cranbury, NJ 08512